NCT05106153View on ClinicalTrials.gov

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions
Healthy Non-dependent, Recreational Sedative UsersAbuse Potential
Interventions
DRUG

Suvorexant

Suvorexant will be administered orally as per assigned treatment sequence.

DRUG

Zolpidem

Zolpidem will be administered orally as per assigned treatment sequence.

DRUG

Seltorexant

Seltorexant will be administered orally as per assigned treatment sequence.

DRUG

Placebo

Placebo will be administered orally as per assigned treatment sequence.

Trial Locations (1)

66212

Altasciences Inc., Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05106153 - A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem | Biotech Hunter | Biotech Hunter